BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
May 05, 2003
 |  BioCentury  |  Product Development

Apple falls not far from the tree

An under-appreciated aspect of being a larger, more mature biotech company is that opportunities unexpectedly present themselves. A case in point is Neurocrine Biosciences Inc., which received a call last quarter from Pharmacia Corp., offering a licensing opportunity for the pharma company's PnU 142,774 sexual dysfunction compound.

Pharmacia divested the compound to satisfy merger requirements as part of its acquisition by Pfizer Inc. (PFE, New York, N.Y.), which sells the blockbuster erectile dysfunction drug Viagra sildenafil. NBIX and PFE are developing NBIX's...

Read the full 408 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >